Theriva Biologics
TOVX
61 hedge funds and large institutions have $64.2M invested in Theriva Biologics in 2016 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 14 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
9% more funds holding
Funds holding: 56 → 61 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
15% less capital invested
Capital invested by funds: $75.5M → $64.2M (-$11.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.93M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.77M |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$1.52M |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.34M |
| 5 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$584K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$2.35M |
| 2 |
William Blair & Company
Chicago,
Illinois
|
-$1.07M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$987K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$339K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$320K |
TOVX Hedge Fund Activity: Q2 2016 in Review
61 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q2 2016, worth a combined $64.2M — down 15% from $75.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new TOVX positions and 14 closed out — a net gain of 5 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $3.93M. The largest seller was MSD Partners, cutting an estimated $2.35M.
- 61 institutional investors held Theriva Biologics (TOVX) as of Q2 2016, up from 56 in Q1 2016.
- Funds reported $64.2M of Theriva Biologics stock for Q2 2016, down 15% quarter-over-quarter.
- 19 funds opened new Theriva Biologics positions in Q2 2016 and 14 closed out, a net change of +5 holders.
- The largest Theriva Biologics buyer in Q2 2016 was BlackRock Fund Advisors, an estimated $3.93M added.
- The largest Theriva Biologics seller in Q2 2016 was MSD Partners, an estimated $2.35M sold.
Based on aggregated 13F filings for Q2 2016.